Cargando…
Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs
A diagnosis of advanced ovarian cancer is the beginning of a long and arduous journey for a patient. Worldwide, approximately half of the individuals undergoing therapy for advanced cancer will succumb to the disease, or consequences of treatment. Well-known and widely-used chemotherapeutic agents s...
Autores principales: | Rath, Kellie S, McCann, Georgia A, Cohn, David E, Rivera, Brian K, Kuppusamy, Periannan, Selvendiran, Karuppaiyah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665575/ https://www.ncbi.nlm.nih.gov/pubmed/23663277 http://dx.doi.org/10.1186/1757-2215-6-35 |
Ejemplares similares
-
Targeting constitutively-activated STAT3 in hypoxic ovarian cancer, using a novel STAT3 inhibitor
por: McCann, Georgia A., et al.
Publicado: (2014) -
NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols
por: Bratasz, Anna, et al.
Publicado: (2008) -
A Novel Curcumin Analog (H-4073) Enhances the Therapeutic Efficacy of Cisplatin Treatment in Head and Neck Cancer
por: Kumar, Bhavna, et al.
Publicado: (2014) -
Mitochondrial-Targeted Curcuminoids: A Strategy to Enhance Bioavailability and Anticancer Efficacy of Curcumin
por: Reddy, Cheruku Apoorva, et al.
Publicado: (2014) -
Inhibition of ALDH1A1 Activity in Cisplatin-Resistant Ovarian Cancer Cells Alters Their Cancer Stemness, Cell Cycle Profile and Mitochondrial Respiration Rate
por: Ramachandran, Ilangovan, et al.
Publicado: (2021)